OSI Pharmaceuticals, Data Presented on Tarceva(R) (erlotinib) at the 12th World Congress on Lung Cancer Meeting

Sep 07, 2007 - OSI Pharmaceuticals, Inc. (Nasdaq: OSIP) provided a summary of selected data from over 58 studies involving the Company's lead product, Tarceva(R), presented during the 12th World Congress on Lung Cancer (WCLC) held September 2-6 in Seoul, Korea. Tarceva is currently approved in the United States as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen, and in combination with gemcitabine chemotherapy for the first-line treatment of locally advanced, unresectable, or metastatic pancreatic cancer... OSI Pharmaceuticals' Press Releases -